Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials
about
Tiotropium versus placebo for chronic obstructive pulmonary diseaseGeneral health checks in adults for reducing morbidity and mortality from diseaseTiotropium versus placebo for chronic obstructive pulmonary diseaseOverview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary diseaseTiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial AsthmaComorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary diseaseTen years of tiotropium: clinical impact and patient perspectivesDifferential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterolLong-acting muscarinic receptor antagonists for the treatment of chronic airway diseasesClinical potential of aclidinium bromide in chronic obstructive pulmonary diseasePrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerationsRelationships of MMP-9 and TIMP-1 proteins with chronic obstructive pulmonary disease risk: A systematic review and meta-analysisDrugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysisMuscarinic antagonists in early stage clinical development for the treatment of asthma.Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials.Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.Risk of acute urinary retention associated with inhaled anticholinergics in patients with chronic obstructive lung disease: systematic review.Risks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to date.Chronic obstructive pulmonary disease: respiratory review of 2014.Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary diseaseQuestionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switchSafety of indacaterol in the treatment of patients with COPD.Outcomes in Cochrane systematic reviews addressing four common eye conditions: an evaluation of completeness and comparability.Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial.Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD.Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular riskSafety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trialHealth promotion or pharmacological treatment for chronic diseases?Safety and tolerability of inhalational anticholinergics in COPDThe Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationalePharmacotherapies for COPD.Management of asthma in the elderly patient.Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.
P2860
Q24194833-B92D418A-C695-47FE-BE88-808DB19B5C78Q24198193-DA09C99E-D376-4DEE-BD74-9E1CF1004328Q24202175-B0C6A524-DA7D-4D8F-8F96-4CC002E20BF0Q26741051-0CF8636E-14F3-4B03-A077-798D1641ABF0Q26780553-52C13C5B-B500-47C3-9C33-929CCBC44973Q26823339-72D7BAD9-5ACD-482A-A228-99647C771E7DQ26823682-B15C9042-56EC-463B-8FC0-8C1A9EA55B01Q26828602-5A667206-887C-4383-88E3-449602FDFC35Q27022636-6E579B15-54E7-4E8F-ACEB-1E1BBB8FB02DQ27023223-E35862E9-1DA8-4820-9A0E-2EA02CFBD633Q27348844-EAFFF122-BDED-40BA-AEC4-89D5C79050D2Q28067579-17B80072-27FF-4A24-A633-E9BAD9DEB0FBQ28076457-FB6133D5-B81C-4EB8-AC73-B9C89BBCFF50Q28258219-C6FEE92F-E3FC-40D0-ABA1-C660FD8FB1F8Q30396144-B95991C9-8630-4226-B22B-A3808CECEF52Q30620671-7A204237-75CA-4073-ACE0-468E21FB73CBQ30820402-EB3486BD-C6E3-42D7-BBE3-30D712BD5302Q30877371-F528FB12-ABA3-4A61-97AB-99038C6AB4C5Q30990525-784910C2-19EB-422E-84A3-5BD7370877DCQ33949299-6BE28371-2DD6-4439-8746-DD9EF914D7A0Q33949317-F0C06381-9934-491C-A1F7-1ACB2C21784EQ34440060-6DBEE8C1-9277-4D98-B461-76C27BE6B891Q34677811-8A63D204-F249-4156-987A-18C7FDFB817CQ34944616-46C180BF-3668-44E4-9EF1-8EB00BFE8A94Q35268351-ADFABC42-2656-4B5D-A957-7A00638D5AE1Q35347819-365B3DAD-37CE-445B-9F6B-471EBB1B5DA9Q35675649-82053591-6546-4ED5-A306-ED6E74851CECQ35762406-E5D26B7A-8EB6-49C3-9A9B-21255A1F4E85Q35766346-72F40C5C-33B7-4ED6-8F71-949DFA54D41FQ35838660-54D61B69-0BAA-4372-A70E-D18E03ADBC17Q35999260-4E386D3D-6747-4D09-83D5-4BCC87E92616Q36251424-A2F39CEC-1552-4505-9B14-86DB3B893D4AQ36412770-1EE5D1A9-C784-40EA-A5A4-E35EE5F3733AQ36456873-6F9D42BC-6492-4C13-840F-4BF9D35F505BQ36478491-AAEE6B5A-E9EA-4847-AF7E-08D45701C876Q36680246-C544C1E0-AC3A-498A-8231-CDA1DAF60354Q36752114-DEAD29B8-3C05-4045-A229-327AF774C9B4Q36843717-3C60804A-7A13-46D7-9731-0374202659D3Q37027409-DE79F80E-1F30-412A-9E10-59F466C88FE5Q37177278-84883621-0589-4289-A0AD-17A0CD6B7067
P2860
Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Mortality associated with tiot ...... f randomised controlled trials
@ast
Mortality associated with tiot ...... f randomised controlled trials
@en
Mortality associated with tiot ...... f randomised controlled trials
@nl
type
label
Mortality associated with tiot ...... f randomised controlled trials
@ast
Mortality associated with tiot ...... f randomised controlled trials
@en
Mortality associated with tiot ...... f randomised controlled trials
@nl
prefLabel
Mortality associated with tiot ...... f randomised controlled trials
@ast
Mortality associated with tiot ...... f randomised controlled trials
@en
Mortality associated with tiot ...... f randomised controlled trials
@nl
P2093
P2860
P31
P921
P3181
P356
P1433
P1476
Mortality associated with tiot ...... f randomised controlled trials
@en
P2093
Curt D Furberg
Paul L Enright
Yoon K Loke
P2860
P3181
P356
10.1136/BMJ.D3215
P407
P433
P50
P577
2011-01-01T00:00:00Z
2011-06-14T00:00:00Z